literature

HIV mutation literature information.

HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting.

PMID: 31117863 2019 Journal of the International Association of Providers of AIDS Care

Table: L74I

HIV-1 Reverse Transcriptase Promotes Tumor Growth and Metastasis Formation via ROS-Dependent Upregulation of Twist.

PMID: 31885806 2019 Oxidative medicine and cellular longevity

Result: The most frequent mutation of resistance to NRTI worldwide is M184V/I, followed by K65R/N, L74V/I, Y115F, and Q151M, and the most prevalent for FSU_A is M184V, followed by K65R/N.

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence.

PMID: 31551948 2019 Frontiers in microbiology

Result: Position L74 has two mutations within this cluster: L74M and L74I, both are described as resistance-related, also described as having minimal effects in INSTI therapy, as previously said.

Result: The resistance-related mutations found in the network were L74M, L74I, T97A, E138K, G140S, Y143R, Q148H, Q148R, N155H, E157Q, G163R, M50I, and S119R.

Table: L74I

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.

PMID: 31430369 2019 The Journal of antimicrobial chemotherapy

Method: Primary NRTI-R substitutions were M41L, K65R/E/N, D67N, T69 insertions, K70E/R, L74V/I, Y115F, Q151M, M184V/I, L210W, T215Y/F and K219E/Q/N/R in RT.

Table: L74I/V

HIV-1 Integrase Resistance among Highly Antiretroviral Experienced Patients from Morocco.

PMID: 31307042 2019 Intervirology

Abstract: The major INSTI resistance mutations at positions 66, 92, 118, 138, 140, 143, 147, 148, 155, and 263 were absent, while two accessory mutations, L74M/I, known to have no clinical impact to INSTIs in the absence of the major resistance mutations, were detected in three samples (3.84%; two CRF02_AG and one CRF01_AE).

Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.

PMID: 31037930 2019 Revista espanola de quimioterapia

Table: L74I

Short Communication: Discordance in Drug Resistance Mutations Between Blood Plasma and Semen or Rectal Secretions Among Newly Diagnosed HIV-1-Infected Thai Men Who Have Sex with Men.

PMID: 29756454 2018 AIDS research and human retroviruses

Abstract: Three participants had DRAMs in anogenital compartments that were not detected in blood plasma-one had DRAMs in semen that was not detected in blood plasma (I54FI) and two had DRAMs in rectal secretions that was not detected in blood plasma (I47IM; K70N, L74I, Y115F, M184V, K103N, V108I, and H221Y).

Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.

PMID: 30409215 2018 AIDS research and therapy

Result: As expected, the number and type of mutations with frequencies > 20% (those within Sanger sequencing-based detection level) matched the cART history of the patient, e.g., the virus from patient SG28 had mutations associated with resistance to ABC (L74I 97.6% frequency), 3TC (M184V 99.7%), and EFV (K103N 98.8%, P225H 99.5%) and had been exposed to RTV, DRV, ABC, 3TC, and EFV; while patient SG86 had a virus with resistance to FTC (M184V 98.9%) and RAL (L74M 97.9%, E92Q 86.1% and T97A 99.8%) after being treated over the years with RTV, LPV, DRV, FTC, TDF, and RAL (Additional file 1: Table S1).

Result: Most of the minority mutations in viruses from both groups of naive patients were observed in the

HIV Reverse Transcriptase and Protease Genes Variability Can Be a Biomarker Associated with HIV and Hepatitis B or C Coinfection.

PMID: 29844604 2018 Scientific reports

Discussion: The codon L74I is selected for by ABC.

Discussion: This patient has the following resistance codons: M41L, D67H, T69N, K70R, L74I, V118I, T215F, K219E, K219Q and K103Y.

Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa.

PMID: 29462322 2018 The Journal of antimicrobial chemotherapy

Abstract: Accessory mutations occurred at a prevalence of 15.1% at the >=20% threshold (23.1% in subtype A, 8.7% C, 11.6% D, 25% G and 23.8% in recombinants), and included L74I/M (10.4%), Q95K (0.5%), T97A (4%), E157Q (0.7%) and G163R/K (0.7%).

Browser Board

Co-occurred Entities

Filtrator